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Mouse models are important tools both for studying 
the pathogenesis of infectious diseases and for the 
preclinical evaluation of vaccines and therapies 
against a wide variety of human pathogens. The use 
of genetically defined inbred mouse strains, 
humanized mice, and gene knockout mice has 
allowed the research community to explore how 
pathogens cause disease, define the role of specific 
host genes in either controlling or promoting disease, 
and identify potential targets for the prevention or 
treatment of a wide range of infectious agents. This 
review discusses several of the most commonly used 
mouse model systems, as well as new resources such 
as the Collaborative Cross as models for studying 
infectious diseases. (Clin Ther. 2019;41:1912e1922) 
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Over the past century, advances in the development of
vaccines, antibiotics/antivirals, and infection control
measures have resulted in major reductions in the
public health burden of infectious diseases. However,
despite these advances, infectious agents continue to
cause significant morbidity and mortality in human
populations, as well as economic disruption in at-risk
communities. The challenges associated with infectious
diseases are illustrated not only by emerging
pathogens, such as HIV or more recent outbreaks of
Zika virus (ZIKV) or Ebola virus, but also by
continuing threats from pathogens such as seasonalinfluenza virus, hepatitis C virus (HCV), dengue virus,
or malaria. Furthermore, the emergence of antibiotic-
or drug-resistant microorganisms and viruses
complicates treatment strategies and further enhances
the risk posed by infectious diseases. Due to these
threats, there is an ongoing need for new strategies to
prevent pathogen transmission, as well as the
development of new vaccines and/or therapeutic
agents. However, the development of new infection
control strategies requires an in-depth understanding
of the target pathogen's biology and disease
pathogenesis, as well as appropriate systems for testing
the safety and efficacy of new treatments or vaccines.
For many pathogens, much of our understanding of
pathogen biology and disease pathogenesis comes from
direct clinical observations in affected patient
populations. This is also the case with vaccines and
antimicrobial/antiviral treatments, in which clinical
trials to assess safety and efficacy data can provide
significant insights into correlates of protection or
disease pathogenesis in human populations.1e3
Furthermore, well-controlled challenge studies have
provided important insights into the host response to
pathogens such as seasonal influenza viruses and
rhinoviruses.4 However, several factors can confound
or limit our ability to study infectious diseases in
humans. Humans can vary greatly in their susceptibility
to certain pathogens: some individuals may be highly
susceptible, whereas others develop only mild disease or
remain asymptomatic. For example, only a small
fraction of West Nile viruseinfected individuals
become symptomatic,5 and individuals vary greatly in
their susceptibility to common pathogens such as
human norovirus.6 This variation confounds analysis in
humans and can be driven by factors such as human or
pathogen genetic variation, underlying health issues, or
demographic factors such as age or sex. Furthermore,
previous pathogen exposure generally results in
immune-mediated protection but, in some instances,
can also drive immune pathology, as illustrated by
dengue hemorrhagic fever/dengue shock syndrome.7
Although it is possible to control for many of these
variables, other confounding factors (eg, pathogen
dose, previous exposure to related pathogens) can be
more difficult to control during natural infection. In
addition to the confounding effects of disease variation
in human populations, it can be difficult to perform
mechanistic analysis or access affected tissues in
humans due to ethical limitations. Although these
problems can sometimes be overcome by using primary
human cells,8e10 it is difficult to accurately model
complex systemic interactions between the pathogen
and host by using these simplified cell culture systems.
Due to the limitations associated with studying
infectious diseases in humans, the research community
has relied on animal models both for studying the
pathogenesis of infection and as platforms for testing
the efficacy and safety of experimental vaccines and
therapies before moving into human studies. These
models provide several advantages, including the
ability to control many of the factors that can cofound
analysis in humans, such as viral dose or underlying
disease states, while also allowing for much more
invasive studies than would be possible in humans. A
wide range of species have been used to
experimentally model host/pathogen interactions,
including nonvertebrate models (eg, Caenorhabditis
elegans), fish (eg, zebrafish), and domesticated
livestock (eg, pigs, cattle), and these systems have
provided important insights into pathogen biology,
zoonotic transmission, and hostepathogen
interactions.11e15 Each of these models offers specific
advantages. For example, C elegans has a short and
well-defined life cycle, is easily manipulated at the
genetic level, the transparent worms are easily
visualized, and they can be infected by a wide variety
of clinically relevant bacterial and fungal pathogens.16
Zebrafish (Danio rerio) are also experimentally
tractable, visually transparent, and mount innate
immune responses that are similar to those seen inhumans. These traits have made zebrafish models
particularly useful for visualizing host inflammatory
responses and studying the role of specific pathogen
determinants and host factors in regulating infection
by several clinically relevant bacterial and viral
pathogens, including Mycobacterium leprae,
Pseudomonas aeruginosa, Shigella flexneri, and
chikungunya virus.11,17 However, the bulk of
laboratory studies have relied on a more limited
number of laboratory species, including mice, rats,
guinea pigs, ferrets, and non-human primates (NHPs),
to study the host response to specific pathogens.
The choice of a specific model system for studying a
given pathogen can be driven by a number of factors,
including permissiveness to infection, physiologic
conservation with humans, reproducibility, ease of
manipulation, safety, and/or cost. However, it is also
generally true that no model organism perfectly
reproduces the response to infection seen in humans,
and in many cases, different animal models can be
used in complementary ways to address specific
questions related to pathogen-induced disease. For
example, NHP species, due to their physiologic
similarity and evolutionary conservation with
humans, are commonly used for studying viral
pathogens such as Ebola virus, Middle Eastern
Respiratory Syndrome coronavirus (MERS-CoV), and
influenza viruses.18e20 However, due to factors such
as the expense associated with NHP studies, as well
as their limited availability, long reproduction times,
and difficulties in manipulating NHPs at the genetic
level, other model systems are used to study these
same pathogens. This is nicely illustrated by influenza
virus, in which NHPs can be used to study viral
pathogenesis.20 However, ferrets are highly
permissive to a wide variety of human respiratory
viruses, including influenza A virus, and the ferret
respiratory tract is anatomically very similar to
humans.21 Therefore, viral transmission and
pathogenesis studies are often performed in ferret
models, which in addition to reproducing many
aspects of human influenza pathogenesis, are lower
cost and more readily accessible than NHPs.20
Furthermore, although mice are generally not useful
for studying influenza virus transmission, they have
historically been the preferred model system for
studying influenza-specific immunity due in part to
the availability of well-defined immune reagents and
gene-specific knockout mice.20,22
Although different animal models are appropriate
for the study of specific pathogens, or for studying
specific aspects of pathogen biology or disease
pathogenesis, the laboratory mouse is one of the
most commonly used animal models for studying
infectious diseases. The dominance of the mouse as a
model system is driven by several factors, including
their relatively low cost, ease of housing, and their
rapid reproduction times and large litter sizes.23
Importantly, the availability of inbred mouse strains,
in which every mouse in the strain is essentially
genetically identical, as well as genetically modified
mice lacking specific host genes,24,25 has allowed the
scientific research community to study how specific
host genes affect the response to pathogen challenge
while also promoting understanding of the host
immune system and its role in protecting from
pathogen challenge or mediating vaccine-induced
immunity.26
Mouse models do have limitations, including
physiologic differences that limit how well mice
reproduce key aspects of hostepathogen interactions,
such as efficient influenza virus transmission.22
Genetic differences between mice and humans can
also interfere with a pathogen's ability to replicate or
cause human-like disease outcomes in mice.27e29
However, despite these limitations, mouse models
provide a number of advantages for studying
hostepathogen interactions. Furthermore, as
discussed later, in some instances in which standardFigure 1. Examples of mouse model platforms used in inmouse models are not useful for working with a
specific pathogen, the availability of genetically
modified mice, humanized mouse models, or
genetically diverse mouse populations can sometimes
be used to overcome these difficulties and allow mice
to be useful tools for studying hostepathogen
interactions. Therefore, given the importance of the
laboratory mouse as a model system for studying
infectious diseases, the remainder of this review
focuses on some of the major types of mouse models
and their utility for studying infectious diseases
(Figure 1).STANDARD INBRED MOUSE STRAINS
As noted earlier, one of the major advantages provided
by inbred mouse strains is their reproducibility.
Therefore, inbred strains such as C57BL/6 or BALB/c
mice can be used to study pathogen tropism and
replication kinetics, or compare the virulence of
different pathogen strains in genetically identical sets
of mice. This enables investigators to assess
experimental reproducibility both within and between
laboratories, while controlling for the effect of host
genetics on the response to infection. For infectious
disease studies, the availability of inbred strains
allows investigators to perform replicate studies,
compare results between laboratories, or investigate
how different pathogens, alterations in pathogen
dose, or different treatments affect genetically
identical individuals.23 Another advantage providedfectious disease research.
by inbred mouse strains is the fact that a wide variety
of immune reagents exist for quantifying host
immune responses. These include pathogen-specific,
major histocompatibility complexerestricted T-cell
epitopes and tetramer reagents that enable
quantification of pathogen-specific T cells after
infection or vaccination in specific mouse genetic
backgrounds. Therefore, inbred mouse strains have
also been an invaluable resource for studying T-cell
responses against viruses such as lymphocytic
choriomeningitis virus or influenza A virus,30,31 and
these systems have been instrumental in advancing
our understanding of the immune system.30 In
addition to providing reproducible, well-characterized
models for studying the biology of infection and
pathogen-specific immunity, the availability of gene-
specific knockouts on defined mouse genetic
backgrounds (eg, C57BL/6) has been used by the
research community for >25 years to study the role
of specific host genes in the response to
infection.32e35 By comparing wild-type mice versus
mice knocked out for a specific gene on the same
genetic background, investigators can test the specific
effect of that gene on pathogen-induced disease or
immunity while controlling for effects of the
remainder of the genome.
IMMUNODEFICIENT MOUSE MODELS
Although many medically relevant pathogens are
capable of replicating and causing disease in standard
laboratory mouse strains, many pathogens, including
viruses such as ZIKV, human norovirus, and
Crimean-Congo hemorrhagic fever virus, replicate
poorly and/or fail to cause disease in standard mouse
strains.36e38 For a subset of these pathogens, it is
possible to use mice that lack key aspects of the host
immune system, which can range from broadly
immunodeficient mouse strains such as SCID or
RAG-1 knockout mice that lack functional T and B
cells,36 to mice that lack specific immune pathways
such as the type I interferon system.38,39 The utility
of broadly immunodeficient models for studying
infectious diseases is illustrated by human norovirus,
a pathogen for which animal models were lacking
until the demonstration that the virus can replicate in
mice lacking a functional adaptive immune system.36
Furthermore, mice that specifically lack a functional
type I interferon system have been used to develop
models for a number of important human viruses,39including ZIKV, Crimean-Congo hemorrhagic fever
virus, dengue virus, and yellow fever virus.40e43 For
example, ZIKV, which caused a major epidemic in
2015e2016 associated with severe birth defects
(reviewed elsewhere44), fails to replicate efficiently in
wild-type mice due to the virus's inability to
efficiently antagonize the STAT2 signaling protein in
the mouse type I interferon system.27 To overcome
this limitation, investigators have taken advantage of
mice that lack a functional type I interferon system
due to the ablation of the type I interferon receptor
or essential interferon signaling molecules such as
STAT1.40 Unlike wild-type mice, these interferon-
deficient mouse strains are susceptible to ZIKV
infection and have been useful as platforms for
studying the pathogenesis of ZIKV-induced birth
defects or for testing potential ZIKV therapies.45,46
GENETICALLY HUMANIZED OR HUMAN
TISSUE XENOGRAFTED MICE
Although immunodeficient mice are useful systems for
studying viruses such as ZIKV, in other instances it is
necessary to introduce specific human genes or
engraft human cells or organ systems into the mouse
to generate infectious disease models. In cases in
which mice are nonpermissive for infection by a
pathogen, the introduction of one or a small number
of pro-viral genes, such as mouse entry receptors,
may be sufficient to allow pathogen replication and
disease. These types of “genetically humanized” mice
have been used for a number of viruses, including
measles virus and the MERS-CoV.47e49 In the case of
MERS-CoV, mouse cells are nonpermissive for viral
infection,50 and this host range restriction can be
overcome by expressing the human version of the
viral receptor protein, dipeptidyl peptidase IV
(DPP4).51e55 Two amino acid differences between
mouse and human DPP4 are responsible for this
difference in receptor function,29 and the expression
of a full-length human DPP4 molecule in the mouse
or introducing the 2 human amino acid changes into
the mouse DPP4 molecule makes mice permissive for
MERS-CoV replication.51e55
Although simply expressing a single human gene is
sufficient to make mice permissive for MERS-CoV,
for some of these models, it is still necessary to allow
the virus to adapt to the mouse to achieve full
virulence.52 In other cases, such as measles virus, it is
necessary to introduce a human receptor molecule
(CD150), while also ablating components of the host
antiviral response to make mice fully permissive for
infection.49 Alternatively, for viruses such as ZIKV,
in which the block on viral replication in the mouse
is due to an inability of ZIKV to efficiently
antagonize the STAT2 component of the type I
interferon signaling pathway,27 replacing the mouse
STAT2 gene with the human STAT2 gene was used
to generate a fully immunocompetent mouse model
of ZIKV infection and disease.56
Although genetically humanized mouse strains can
be powerful tools for modeling infection with some
viral pathogens, for other viruses, such as HCV,
several genes regulate host range, making it difficult
to fully recapitulate the human factors that promote
pathogen replication or disease in either standard or
genetically humanized mice.57,58 Furthermore,
differences between the mouse and human immune
system may limit the utility of standard or modified
mouse strains as models for studying host immune
responses or disease pathogenesis.59 To overcome
these problems, the research community has used
mice engrafted with human tissues to model human
responses to infection. These human tissue
xenografted mice take advantage of the fact that mice
lacking a functional adaptive immune system (eg,
SCID or RAG-1 knockout mice) are permissive for
engraftment by human immune cells, while removal
of other mouse genes, such as the common gamma
chain of the interleukin-2 receptor, results in
improved engraftment. These models can be used to
study multiple aspects of the host innate and adaptive
immune response, and can also be engrafted with
solid organ tissues from humans.59,60 Furthermore,
because immune cells and other tissues from the same
individual can be used to generate cohorts of
humanized mice, it is possible to test responses in sets
of individuals carrying tissues from the same genetic
background.61 Although a detailed description of the
different types of humanized mouse models, and the
methods used in their development is beyond the
scope of the present review, we refer the reader to
several recent reviews that nicely summarize the
current state of xenograft mouse development.59,62
Mice with xenografted human immune systems
have been used to study the pathogenesis of a wide
range of infectious agents, including Plasmodium
falciparum (malaria), Mycobacterium tuberculosis,
dengue virus, and influenza virus.59,61 These modelshave been particularly useful for studying HIV,
including analysis of viral and host factors that
promote viral replication, HIV interactions with the
host immune response, and as platforms for testing
therapeutic approaches for controlling or curing HIV
infection.62 Although the majority of studies using
xenografted mice have focused on human immune
cells, these models can also be used to evaluate
pathogen interactions with solid organs. Human liver
xenograft mice have been shown to support
replication of hepatitis viruses B, C, D, and E, and
these models are useful for studying the pathogenesis
of virus-induced liver injury, and as platforms for
evaluating potential therapies to treat acute and
chronic HCV and hepatitis B virus infection.59
Likewise, human intestinal xenograft models have
been used to study Entamoeba histolytica infection,
while lung xenografts have been shown to support
Nipah virus infection.60,63 Despite their utility,
human xenograft models do have limitations,
including issues with engraftment efficiency/tissue
rejection and an inability to fully recapitulate human
immune responses, such as antigen-specific antibody
responses.59 However, despite these limitations, these
model systems represent an important set of tools for
modeling pathogen interactions with human cells and
tissues in vivo, and as these models continue to
improve, they are likely to gain even greater use
within the infectious disease research community.
THE COLLABORATIVE CROSS GENETIC
REFERENCE POPULATION
As discussed earlier, one of the major reasons that
inbred mouse strains and their genetically modified
derivatives are such powerful systems for studying
infectious diseases is their reproducibility. The ability
to use sets of genetically identical animals from an
individual inbred mouse strain (eg, C57BL/6J) allows
for replicate experiments and comparison of
responses across different treatments (eg, pathogen
dose, strain, therapies). However, the reliance on one
or even a few mouse strains means that investigators
are evaluating pathogen infection in a limited number
of genetic backgrounds, which is unlikely to
recapitulate the phenotypic diversity seen within
genetically diverse human populations upon pathogen
exposure. Therefore, to model how pathogens
interact with genetically diverse populations, a
number of investigators have used genetically diverse
mouse populations such as the Collaborative Cross
(CC).
The CC is a panel of recombinant inbred mouse
strains designed to model the genetic diversity present
in human populations and promote the identification
of polymorphic host genes that contribute to
phenotypic variation across the population.64 The
CC is derived from 8 parental mouse strains,
including 5 classical laboratory strains (C57BL/6J,
129S1/SvImJ, A/J, NOD/ShiLtJ, and NZO/HiLtJ), as
well as 3 wild derived strains from 3 Mus musculus
subspecies (domesticus [WSB/EiJ], casteneus [CAST/
EiJ], and musculus [PWK/PhJ]), which provide the
majority of the genetic diversity found in the CC.65,66
The 8 founder strains were intercrossed by using a
funnel breeding system to produce progeny mice that
were genetic mosaics of the original 8 founder
strains. These mice were then bred to homozygosity
to create recombinant inbred CC mouse strains.64
There are currently >60 inbred CC strains that areFigure 2. Strategies for using the Collaborative Cross (C
potential strategies for using the CC mouse pop
how host genetic factors affect disease pathoge
8e16 strains) can be infected with a pathogen
their susceptibility to pathogen-induced disea
variation in the host response to infection. (C
interest (eg, pathogen-induced disease), investig
phenotype to develop a new model system.75,79
the phenotypic variation in the CC to perform
morphic host genes associated with variation iavailable to use by the scientific community (https://
csbio.unc.edu/CCstatus/index.py). Because the CC
strains are inbred, they allow investigators to perform
the same types of comparative studies across
reproducible sets of animals that are conducted with
standard inbred strains (ie, C57BL/6). However,
because each CC strain possesses a unique
combination of genetic material from the original 8
founder strains, CC strains often exhibit unique
phenotypes not observed in the original 8 founder
strains,64 resulting in the development of new mouse
models that better reproduce specific aspects of
human disease (Figure 2). Furthermore, by
comparing phenotypes between CC strains,
investigators can test how host genetic variation
affects specific phenotypes, including the response to
pathogen challenge,64 and then map the specific
genetic loci responsible for this variation.
The CC was designed to map quantitative trait loci
(QTL) associated with phenotypic variation across theC) in infectious disease studies. (A) An overview of
ulation for developing new animal models or studying
nesis. (B) Sets of mice from a panel of CC strains (eg,
of interest and the strains evaluated for variation in
se, their ability to support pathogen replication, or
) If strains exhibit variation in the phenotype(s) of
ators can select a CC strain or strains with the desired
(D) Alternatively, investigators can take advantage of
genetic mapping studies to identify and study poly-
n infection outcomes.71,73,74.
CC strains, and several groups have taken advantage
of this capability to map QTL associated with
variation in the host response to infection. During the
development of the CC, several groups used
incompletely inbred populations of CC mice known
as the pre-CC to assess variation in susceptibility to
viral, bacterial, and fungal pathogens.64 The first
study examining infectious disease susceptibility in
the pre-CC was by Durrant et al,67 who analyzed a
panel of pre-CC lines for variation in susceptibility to
Aspergillus fumigatus. These studies found high levels
of variation in survival time across pre-CC lines, and
mapped several QTL associated with A fumigatus
susceptibility. The pre-CC, as well as fully inbred CC
strains, have also been used to study the impact of
host genetic variation on bacterial infections. Vered
et al68 evaluated pre-CC lines for variation in
susceptibility to Klebsiella pneumoniae, and identified
3 QTL associated with variation in K pneumoniae
survival. A second study, by Zhang et al,69 evaluated
variation in susceptibility to Salmonella enterica
challenge in a panel of fully inbred CC strains and
identified several genetic loci associated with
variation in bacterial load. Several studies have also
used either the pre-CC or F1 crosses between fully
inbred CC strains to map QTL associated with
variation in virus-induced disease. Studies detailed by
Maurizio et al,70 Ferris et al,71 and Bottomly et al72
reported high levels of variation in influenza virus
susceptibility that was highly heritable. Ferris et al71
went on to identify several QTL associated with
variation in influenza-induced disease susceptibility,
including the identification of previously unidentified
variants in the influenza resistance gene, Mx1. The
pre-CC was also used by Gralinski et al73 to identify
4 unique genetic loci associated with variation in
susceptibility to the SARS-coronavirus (SARS-CoV).
Detailed analysis of one of these loci, a QTL on
chromosome 3 associated with variation in vascular
cuffing in the lungs of SARS-CoVeinfected mice,
identified the gene Trim55 as a high-priority
candidate gene under the locus. Validation studies
using Trim55 knockout mice showed that TRIM55
plays an important role in regulating virus-induced
inflammation within the lungs of SARS-
CoVeinfected mice.73 Follow-up studies by Gralinski
et al74 used F2 mapping approaches to identify
additional genetic loci regulating SARS-CoV
susceptibility in susceptible or resistant CC strains.This analysis identified 5 additional genetic loci
associated with variation in SARS-CoVeinduced
disease, and identified and validated the gene for the
TLR4 adaptor Ticam2, as a contributor to variation
in SARS-CoVeinduced disease susceptibility.
In addition to utilizing the CC for identifying
polymorphic host genes that regulate pathogen
susceptibility, investigators have taken advantage
of the high levels of phenotypic variation in CC
strains to develop improved models of pathogen-
induced disease. This is perhaps best illustrated by
the studies in Rasmussen et al,75 who used the
CC to develop new mouse models of Ebola
viruseinduced hemorrhagic disease. Ebola virus
causes a wide range of symptoms in humans,
including hemorrhagic disease; however, although
the use of mouse-adapted Ebola virus in standard
mouse strains has been useful for studying disease
pathogenesis and testing vaccines/therapies, these
models do not fully reproduce the disease signs
seen in infected humans.76 Rasmussen et al
evaluated a panel of F1 crosses between fully
inbred CC strains for susceptibility to challenge
with mouse-adapted Ebola virus. These studies
found high levels of variation in disease
susceptibility, including the identification of CC
strains that developed severe disease with
hemorrhagic signs and liver damage.75 Studies by
several other groups have identified CC strains
that exhibit novel susceptibility profiles to a wide
range of pathogens, including M tuberculosis,
West Nile virus, SARS-CoV, and influenza
virus.71,73,77e79 These results indicate that by
taking advantage of the genetic diversity present in
the CC, investigators can develop novel models of
pathogen-induced disease that more closely
represent disease phenotypes observed in human
populations. Furthermore, once mouse strains with
novel disease phenotypes have been identified, it is
possible to identify the genetic loci responsible for
these novel disease outcomes71,73 and gain
additional insights into the mechanisms underlying
disease pathogenesis.
CONCLUSIONS
Animal models have been, and continue to be, an
important resource for investigating the mechanisms
underlying infectious disease pathogenesis and as
platforms for testing potential vaccines and therapies.
Mouse models have been a particularly important
resource for studying infection by a wide range of
human pathogens and are widely used for preclinical
screening of vaccines/therapies due to their
reproducibility, low cost, and ease of experimental
manipulation. Although mouse models are not
appropriate for studying some aspects of pathogen-
induced disease, the use of genetically modified
animals and humanized mice allows investigators to
study pathogens that will not replicate efficiently in
species other than humans or chimpanzees (eg, HCV)
and perform mechanistic studies that cannot be
conducted in humans. Furthermore, the availability of
genetically diverse mouse resources such as the CC
allows investigators to test how host genetic diversity
affects the response to infection, while also taking
advantage of the phenotypic diversity in these
resources to develop model systems that better
reproduce aspects of pathogen-induced diseases seen in
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